GlobeNewsWire
23 Sept 2026, 12:45 UTC · 5h ago
Verdict
Headline leans bullish. We score PALI +0.60 across three claims.
Score confirms the headline.
Leans bullish
From its wording — no explicit rating
+0.60strongly bullish
What the story claims
3 claims · scored −1 bearish … +1 bullish · 3 new · 0 priced in
Primary efficacy results from the ASCENTRA-UC Phase 2b study involving approximately 204 patients are expected in the second half of 2027.
Newannounced today, Sept. 23, 2026
So whatThis creates a binary catalyst window in H2 2027, meaning the stock's valuation will likely remain speculative until then.
More positive than 92% of claims this week
Continue reading
5 related stories
More positive than 73% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
Health Canada has cleared the Clinical Trial Application (CTA) for the global Phase 2 ASCENTRA-UC study of PALI-2108.
Newannounced today, Sept. 23, 2026
So whatExpanding to Canada reduces enrollment risk, supporting the target of starting patient dosing in H2 2026.
More positive than 63% of claims this week
The ASCENTRA-UC trial will evaluate once-daily 15 mg and 30 mg doses of PALI-2108 against a placebo.
Newannounced today, Sept. 23, 2026
So whatThe 2-arm dose-ranging design aims to establish the optimal therapeutic window for future Phase 3 trials.
More positive than 41% of claims this week
Which stocks this story touches
More positive than 73% of ticker scores this week
The company received Health Canada CTA clearance, allowing it to expand its global Phase 2b study for PALI-2108.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
17h ago
−4.7%
Price is moving against the score
$1.61 vs $1.69 close before publication (Sep 22) · not market-adjusted
PALI chart →
